Introduction {#sec1}
============

Aliphatic primary amines are represented in a wide range of chemical feedstock and display great biological, pharmaceutical, agricultural, materials, and synthetic applications.^[@ref1]−[@ref6]^ Of late, functionalization of C(sp^3^)-H has emerged as a promising synthetic tool.^[@ref7]−[@ref10]^ The C(sp^3^)-H activated functionalization of secondary and tertiary aliphatic amines is well investigated employing transition-metal catalysts.^[@ref11]−[@ref14]^ However, site-selective functionalization of inactivated C(sp^3^)-H bonds of primary aliphatic amines is more challenging because of their strong nucleophilic, reducing, chelation, and deactivating properties, which may hamper or deactivate catalytic power of the possible metal catalysts. Thus, use of prefunctionalized amines, directing group (DGs), and/or transient DG, their removal after the desired transformation, and intramolecular annulation are frequently exercised in the metal catalysis processes.^[@ref15]−[@ref18]^ A limited number of approaches were devoted for the site-selective C(sp^3^)-H functionalization of primary aliphatic amines, such as Zr^IV^/Ni^II^-catalyzed α-selective cyclization,^[@ref19],[@ref20]^ Pd^II^-tuned β-arylation,^[@ref21]^ Pd^II^-Ag^I^ guided γ-substitution,^[@ref18],[@ref22]−[@ref25]^ and Pd^II^-activated δ-arylation.^[@ref26],[@ref27]^ However, a metal-free C(sp^3^)-H functionalization is always a more appealing strategy to be developed for minimizing the harmful impact on nature.^[@ref28]−[@ref30]^

So far, few nonmetallic C(sp^3^)-H activation processes were developed utilizing pyridine-*N*-oxide, TBAI/TBHP, DTBP, hypervalent iodines, and iodine.^[@ref31]−[@ref37]^ Molecular iodine has emerged as an excellent catalyst^[@ref38]−[@ref43]^ because of its high solubility in the reaction media, easy handling, low cost, and environmentally friendly nature in comparison to heavy metals. The cyclization through C(sp^3^)-H functionalization has become an indispensable synthetic strategy to deliver invaluable heterocyclic molecules.^[@ref44]−[@ref50]^ Earlier, Schafer et al. introduced an α-C(sp^3^)-H activated intramolecular 6-annulation with the Zr(NM~2~)~4~ catalyst ((i), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref19]^ We established NiX~2~·*n*H~2~O-catalyzed bimolecular 5-annulation ((ii), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref20]^ Chen et al. reported Pd(OAc)~2~-PhI(OAc)~2~-mediated intramolecular 4-annulation of protected primary aliphatic amines ((iii), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref26]^ The major limitations of these methods are the utilization of toxic heavy metal catalysts, intramolecular cyclization ((i) and (iii), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), severe water susceptibility to catalysis ((ii), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), high reaction temperature (145 °C), requirements of a stoichiometric oxidant \[PhI(OAc)~2~\] and base in excess (2.5 equiv.), and slow reaction rates. In a continuous effort to synthesize novel polycyclic heteroaromatics for design, synthesis, and fabrication of new organic nanomaterials to discover their innovative organic electronic properties^[@ref51]−[@ref54]^ for developing new generation devices,^[@ref55],[@ref56]^ herein, we disclose a direct C--O bond forming 5-annulation ((iv), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) and 6-annulation ((v), [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) through C(sp^3^)-H functionalization through nonmetallic catalysis to furnish polycyclic *N*,*O*-heteroaromatics.

![Annulation with Primary Aliphatic Amine-C(sp^3^)-H](ao9b03501_0001){#sch1}

1,3-Oxazoles are a fundamental class of five-membered privileged heterocyclic motifs that have profound importance in natural products, pharmaceuticals, agrochemicals, and materials.^[@ref57]−[@ref62]^ For instance, the benzoxazole-based natural product nataxazoles (**A**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) displayed anticancer, antibacterial, and cytotoxic bioactivities,^[@ref61]^ and the heterocycle-grafted graphene oxide organic material was used as a valuable high-performance supercapacitor electrode (**B**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref62]^ The widespread application of the heterocycles led to the development of several synthetic strategies such as Cu^II^-catalyzed oxidative cyclization,^[@ref63]^ \[2 + 2 + 1\] annulation of alkyne and nitrile,^[@ref64]^ dehydrogenative annulation,^[@ref65]^ Pd^II^-catalyzed annulation of amides,^[@ref66]^ and photocatalytic Ru catalysis.^[@ref67]^ The importance of metal-free synthesis was also realized using organocatalysis,^[@ref68]^ cyclization of aminoacids,^[@ref69]^ PhIO-TfOH,^[@ref70]^ and dehydrogenative I~2~-TBHP cyclization.^[@ref71]^ 1,4-Oxazines have shown immense importance in biological and material sciences.^[@ref72]−[@ref80]^ For example, oxazine derivatives (**C**, **D**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) were employed in the treatment of neurodegenerative, inflammatory,^[@ref78]^ autoimmune, and cardiovascular^[@ref79]^ disorders, and the thin films of naphthoxazine-based materials (**E**, [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) showed unique surface plasmon polarization with emission enhancement properties. Syntheses of oxazines were mainly achieved through Pd^II^ catalysis of bisvinylphosphate^[@ref81]^ and intramolecular cyclization with the CuI-catalyst^[@ref82]^ and triphenylphosphine.^[@ref83]^

![Important benzoxazole and oxazine analogues.](ao9b03501_0013){#fig1}

Results and Discussion {#sec2}
======================

Intending to synthesize the heterocyclic moiety through nonmetallic amine-C(sp^3^)-H functionalization, at first, we focused on α-C(sp^3^)-H functionalization, and for that, we have selected phenanthrenequinone (**1a**) and benzylamine (**2a**) as two reacting partners, which might yield the corresponding oxazole derivative (**4a**, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The feasibility of the 5-annulation catalysis was examined with 20 mol % triflic acid and camphor sulfonic acid (CSA) as possible catalysts (entries 1, 2, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) under aerobic conditions in toluene at 100 °C (bath temperature) for 15 h. In these cases, the α,α-C(sp^3^)-H-amine derived oxazole was obtained successfully in moderate yields (48, and 57%, respectively). To our delight, on the use of I~2~, the reaction was rapidly completed (2 h), and the yield significantly improved (79%, entry 3). Keeping I~2~ as a promising catalyst (20 mol %), different solvents such as protic EtOH (entry 4), relatively low boiling point EDC (entry 5), and highly polar DMF and DME (entries 6, 7, respectively) were screened to achieve moderate to high yields (58--78%). Gratifyingly, dioxane proved to be the best reaction medium providing the desired product (**4a**) rapidly (1 h), and **4a** was furnished almost in quantitative yield (98%, entry 8). The increase in reaction time (6 h) resulted in a decrease in yield of the desired product (95%, entry 9). In the absence of oxygen (argon atmosphere), the yield drastically dropped to 22% even after continuation of the reaction for 24 h (entry 10). Surprisingly, the change of catalyst loading (entries 11, 12) led to a considerable decrease in the yield of the desired product (**4a**). The 5-annulation was unsuccessful in the absence of the catalyst under the same reaction conditions (entry 13).

###### Development of C(sp^3^)-H-Functionalized 5-Annulation[a](#t1fn1){ref-type="table-fn"}

![](ao9b03501_0003){#gr12}

                 entry                    catalyst     solvent[b](#t1fn2){ref-type="table-fn"}  time (h)    yield (%)[c](#t1fn3){ref-type="table-fn"}
  ------------------------------------ -------------- ----------------------------------------- ---------- -------------------------------------------
                   1                    triflic acid                   toluene                  15                             48
                   2                        CSA                        toluene                  15                             57
                   3                        I~2~                       toluene                  2                              79
   4[d](#t1fn4){ref-type="table-fn"}        I~2~                        EtOH                    1.5                            58
                   5                        I~2~                         EDC                    1.5                            70
                   6                        I~2~                         DMF                    1.5                            75
                   7                        I~2~                         DME                    1.5                            78
                   8                        I~2~                       dioxane                  1                              98
   9[d](#t1fn4){ref-type="table-fn"}        I~2~                       dioxane                  6                              95
   10[e](#t1fn5){ref-type="table-fn"}       I~2~                       dioxane                  24                             22
   11[f](#t1fn6){ref-type="table-fn"}       I~2~                       dioxane                  12                             79
   12[g](#t1fn7){ref-type="table-fn"}       I~2~                       dioxane                  1                              94
                   13                                                  dioxane                  24             ND[h](#t1fn8){ref-type="table-fn"}

Reaction conditions: **1a** (0.5 mmol), **2a** (0.5 mmol), catalyst (20 mol %).

Volume of solvent: 2 mL.

Yield of pure **4a** after silica gel column chromatography using ethyl acetate in petroleum ether as an eluent.

Under reflux (∼80 °C for EtOH and ∼100 °C for dioxane).

Under argon.

Catalyst (15 mol %).

Catalyst (25 mol %).

Not detected.

The substrate scope of the dual α-C(sp^3^)-H-functionalized 5-annulation was investigated using a wide range of primary aliphatic amines (**2a**--**f**, [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) and aromatic 1,2-diketones (**1**) under the developed optimized reaction conditions (entry 8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The ester-substituted primary amine (**2b**, [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) and phenanthrenequinone (**1a**) as well as pyrene-based 1,2-diketones (**1b**) smoothly transformed into the corresponding desired products (**4b**, **4c**, [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}), which did not require any change in the developed reaction conditions (entry 8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}).

![Dual α-C(sp^3^)-H-Functionalized 5-Annulation to Oxazoles](ao9b03501_0009){#sch2}

The presence of weak hydrophobic interactions through the installation of the hydrocarbon residue is frequently needed for the generation of organic nanomaterials.^[@ref51]−[@ref56]^ Herein, use of *n*-butyl-, decyl-, and phenethylamine (**2c**--**e**) was successful in achieving corresponding potent nanobuilding blocks (**4d**--**f**) with high yields (77--90%) in 2--4 h. Hydrogen bonding is one of the most common gluing interactions operating between the organic nanounits, and the synthesis of an oxazole derivative (**4g**) bearing the −OH group worked well with the coupling partner aminoethanol (**2f**).

After dual α-C(sp^3^)-H functionalization of various primary aliphatic amines, we turned our attention for making the strategy more diverse and general through replacement of one of the α-C(sp^3^)-H by −CO~2~H so that inexpensive and easily available amino acids may be employed as the key substrate for decarboxylative 5-annulation. To our delight, the attempted reaction between phenyl glycine (**3a**) and phenanthrenequinone (**1a**) rapidly (3 h) furnished the desired product (**4a**, [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}) under similar reaction conditions (entry 8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) with high yield (80%). Many aliphatic and aromatic residues, phenolic −OH, alcoholic −OH, −SMe, and chirality were well tolerated to produce a variety of polycyclic oxazoles in high yield, and reaction rates were faster on use of a wide range of amino acids (**3a**--**k**). In a competitive experiment of cleaving C(sp^3^)-H versus −CO~2~H in glycine (**3k**) possessing two α-C(sp^3^)-H groups as well as one α-CO~2~H group furnished oxazole derivative **4p** through a decarboxylation process exclusively, rather than formation of the −CO~2~H group tethered oxazole derivative (**4q**) by functionalization of consecutive two C(sp^3^)-H. Thus, C-CO~2~H breaking is more favorable under the catalytic conditions with respect to C(sp^3^)-H cleavage. The structure of compound **4j** is established by single-crystal X-ray diffraction analysis.^[@ref84]^ Further, 2,7-dibromo-phenanthrene-9,10-dione under optimized reaction conditions (entry 8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) led to exclusive construction of corresponding oxazole derivatives **4r** and **4s** through the decarboxylation process.

![Decarboxylative α-C(sp^3^)-H-Functionalized 5-Annulation](ao9b03501_0008){#sch3}

Next, we envisioned functionalization of both α-C(sp^3^)-H and β-C(sp^3^)-H under the reaction conditions leading to the construction of valuable six-annulated polycyclic oxazine derivatives ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). To verify that we have employed primary amines (**5**) possessing a β-C(sp^3^)-H, which was obtained by just replacing the α-H with an alkyl group of **2** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). To our surprise, six-annulated desired oxazine derivative **6a** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}) was rapidly (2 h) formed upon treatment of 1-phenylethylamine (**5a**) with 9,10-phenanthrenequinone (**1a**) under the catalytic conditions in high yield (80%). Herein, phenyl (**6a**, **6b**, **6e**, **6g**, **6i**) and activated aromatic residues such as naphthyl (**6c**), 4-tolyl (**6d**), 4-hydroxyphenyl (**6h**), and methyl \[γ-C(sp^3^)-H, **6e**) as well as the ester functionality (**6g**, **6h**) are well tolerated to furnish selectively polyaromatic oxazine systems (**6a**--**i**) in 2--8 h with high yields (68--81%). In the presence of the cyclohexyl group, the desired product tautomerized to **6f** through migration of a double bond. Probably, high steric and electronic repulsion appeared due to the presence of axial and equatorial C--H bonds (cyclohexyl residue) in the close vicinity of the C=N bond and lone pair in **6f**^i^, which led to release of unwanted repulsive forces to obtain thermodynamically stable and fully aromatic 3-cyclohexyl-4*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazines (**6f**).

![α,β-C(sp^3^)-H-Functionalized 6-Annulation to Oxazines](ao9b03501_0007){#sch4}

To understand the reactivity and versatility of the C(sp^3^)-H-functionalized annulation strategy, we have replaced the R group (**5**, [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}) by a −CO~2~Et group in the aliphatic amines (**7a**--**c**, [Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). To our surprise, a 6-annulation reaction occurred under the reaction conditions through α-C(sp^3^)-H functionalization of the primary aliphatic amines as well as an O--C coupling with the ester group involving the release of −OEt to afford valuable polynuclearoxazine-2-ones (**8a**--**c**). The molecular-iodine-catalyzed synthesis of 3-alkyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazin-2-one (**8**) was rapid (2--4.5 h) and high yielding (72--77%). Formation of all new oxazoles, oxazines, oxazine-2-ones, and analogues was confirmed by spectroscopic analyses, recorded melting points (Supporting Information), and also single-crystal X-ray diffraction analyses of **4j**([@ref84]) and **6a**.^[@ref85]^ It is worthy to note that, although most of the reported metal catalysts for C--H-activated functionalization reactions are moisture-sensitive, herein, the catalyst I~2~ efficiently performed the diverse C--H-functionalized annulation catalysis even in the presence of water.

![α-C(sp^3^)-H-Functionalized Lactonization to Oxazine-2-ones](ao9b03501_0006){#sch5}

Out of several possibilities,^[@ref86]−[@ref91]^ the current catalysis is expected to pass through the initial formation of a monoimine **IA** and **IB**, which may proceed through activation of an α-C(sp^3^)-H subsequent formation of a five-membered transition state (**II**) with the catalyst (I~2~) to intermediates **IIIA** and **IIIB** ([Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}). The formation of intermediates **IA** and **IB**, as well as **IIIA** and **IIIB**, was detected in the mass spectral analyses of the ongoing reaction ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b03501/suppl_file/ao9b03501_si_001.pdf)). A second α-C(sp^3^)-H activation of **IIIA** with the close vicinity of the iodine substituent possessing lone pairs and larger size (**IV**) may release HI to furnish the dual α-C(sp^3^)-H-functionalized 5-annulated product (**4a**, path a). On the other hand, decarboxylative α-C(sp^3^)-H 5-annulation of **IIIB** is possibly passing through a six-membered transition state (**V**) to **4i** (path b). In both cases, the generated HI is expected to oxidize immediately by aerial O~2~ to regenerate I~2~ for the next catalytic cycle. The role of inexpensive O~2~ as an oxidant was verified (entry 10, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) by performing the reaction in the absence of O~2~ (argon atmosphere) where the yield of **4a** drastically reduced (22%) in the presence of the catalyst. Herein, decarboxylation through a six-membered transition state (**V**, path b, [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}) is energetically more favorable than the second α-C(sp^3^)-H activation by a four-membered one (**IV**, path a), which was reflected in the 5-annulation of glycine to produce exclusively **4p** instead of **4q**.

![Mechanistic Hypothesis for I~2~-Catalyzed 5-Annulation](ao9b03501_0005){#sch6}

The 6-annulation is expected to proceed in a similar fashion through the initial formation of a monoimine **VI** ([Scheme [7](#sch7){ref-type="scheme"}](#sch7){ref-type="scheme"}), which may proceed via an iodine-mediated activation of an α-C(sp^3^)-H through an eight-membered transition state (**VII**). Removal of HI leads to the generation of the putative intermediate **VIII**, which further tautomerizes to transition state **IX**. It undergoes O--C coupled cyclization, oxidative C=N formation (**X**) to desired product **6**, and the regeneration of molecular iodine for the next catalytic cycle.

![Mechanistic Hypothesis for I~2~-Catalyzed 6-Annulation](ao9b03501_0004){#sch7}

Next, we moved to investigate morphological characteristics of some final compounds through fabrication by the spin coating method. Thus, we choose three representative compounds, namely, **4n**, **6b**, and **6h**, carrying strong aromatic electron clouds, polar functional groups, phenolic −OH, van der Waals interaction, and π--π stacking attractive forces, which might operate in between the small organic molecules (nanobuilding block) to fabricate the desired organic nanomaterials through the spin coating, deep coating, and Langmuir--Blodget techniques. The SEM images of the spin-coated materials displayed nanomorphologies such as the existence of the rod-like structure of compound **4n** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), the sheet-like architecture of compound **6b** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}), and the flower-like nanostructure of compound **6h** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). We are now investigating the development of their innovative optical, nanoelectronics, and *I*--*V* characteristics for potential application in the valuable solar cell, supercapacitor, and nonvolatile memory devices.

![Rod-like nanostructures of **4n** observed in SEM imaging.](ao9b03501_0011){#fig2}

![Sheet-like nanostructures of **6b** observed in SEM imaging.](ao9b03501_0012){#fig3}

![Flower-like nanostructures of **6h** observed in SEM imaging.](ao9b03501_0010){#fig4}

Conclusions {#sec3}
===========

In conclusion, we have demonstrated a general nonmetallic synthetic strategy for diverse C(sp^3^)-H functionalization of unprotected primary aliphatic amines with an I~2~ catalyst to intermolecular 5- and 6-annulation. A variety of unsubstituted, substituted, acid, ester, alcohol, and thiol derivatives of primary amines and their chiral analogues were successfully coupled to 1,2-diketone analogues to obtain a series of new polyaromaticoxazoles, 1,4-oxazines, oxazin-2-one, and chiral heterocycles with rapid reaction rates and high yields. This newly established I~2~-catalyzed α,α-C(sp^3^)-H, decarboxylative α-C(sp^3^)-H, lactonized α-C(sp^3^)-H, and α,β-C(sp^3^)-H-functionalized 5- and 6-annulation as well as α-C(sp^3^)-H-activated 6-lactonization of primary aliphatic amines will open up another avenue for developing a metal-free sustainable strategy for simple, rapid, and diverse construction of functional-group-decorated heteroaromatics, which will find considerable application in organic synthesis, medicinal chemistry, materials science, and organic nanoelectronics for smart devices.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

All reagents were purchased from commercial suppliers and used without further purification. Petroleum ether used in our experiments was in the boiling range of 60--80 °C. Column chromatography was performed on silica gel (100--200 and 230--400 mesh). Reported melting points are uncorrected. Prior to melting point determination, recrystallization was carried out; for compounds whose NMR spectra were taken in CDCl~3~, recrystallization was carried out in CDCl~3~, and for those whose NMR spectra were taken in DMSO-*d*~6~, recrystallization was carried out in an ethyl acetate/hexane mixture. ^1^H NMR and ^13^C NMR spectra were recorded at ambient temperature in CDCl~3~/DMSO-*d*~6~ solution. Chemical shifts are reported in ppm (δ) relative to internal reference tetramethylsilane. Coupling constants are quoted in Hz (*J*). Proton multiplicities are represented as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), and m (multiplet). Splitting patterns that could not be interpreted are designated as multiplet (m). Infrared spectra were recorded on an FT-IR spectrometer in thin films. HR-MS data were acquired by electron spray ionization on a Q-tof-micro quadruple mass spectrophotometer. X-ray crystallographic data were taken using an X-ray diffractometry instrument.

General Procedure for the Synthesis of Oxazoles **4a**--**s** (**GP-I**) {#sec4.2}
------------------------------------------------------------------------

To a mixture of phenanthrenequinone (**1**, 1.0 mmol) and amine (**2a**--**f**)/amino acid (**3a**--**k**, 1.1 mmol, 1.1 equiv.) in dioxane (2 mL), I~2~ (20 mol %, 50 mg) was added, and the solution was refluxed under air to complete the reaction, which was monitored by TLC. Dioxane was removed from the reaction mixture, and the residue was purified by silica gel column chromatography using a suitable eluent to afford the desired product.

### 2-Phenylphenanthro\[9,10-*d*\]oxazole (**4a**)^[@ref92]−[@ref94]^ {#sec4.2.1}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and benzylamine (1.1 mmol, 0.12 mL). Purification by column chromatography (8% EtOAc-pet ether) afforded the title compound as a white solid (289 mg, 0.98 mmol, 98% yield). ^1^H NMR (300 MHz, CDCl~3~): δ 7.54--7.59 (m, 3H), 7.61--7.75 (m, 4H), 8.27--8.37 (m, 3H), 8.59--8.66 (m, 3H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 120.7, 120.9, 122.8, 123.3, 123.6, 126.0, 126.1, 126.2, 127.0, 127.1, 127.3, 127.5, 128.8, 129.1, 130.8, 135.4, 144.7, 162.0; FT-IR (KBr, cm^--1^): 708.3, 755.3, 1058.9, 1235.1, 1450.9, 1480.0, 1548.4, 2853.2, 2923.7.

### Ethyl Phenanthro\[9,10-*d*\]oxazole-2-carboxylate (**4b**) {#sec4.2.2}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and ethyl glycinate (1.1 mmol, 112 mg). Purification by column chromatography (8% EtOAc-pet ether) afforded the title compound as a yellow solid (239 mg, 0.82 mmol, 82% yield). mp 168--170 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.50 (t, *J* = 7.2 Hz, 3H), 4.58 (q, *J*~1~ = 6.9 Hz, *J*~2~ = 15 Hz, 2H), 7.49--7.68 (m, 4H), 8.23--8.26 (m, 1H), 8.53--8.59 (m, 3H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 14.3, 29.7, 63.0, 120.3, 121.7, 123.1, 123.4, 123.7, 125.6, 126.9, 127.5, 127.8, 127.9, 129.2, 130.6, 134.7, 146.3, 151.8, 156.3; FT-IR (KBr, cm^--1^): 722.9, 755.4, 1148.0, 1278.8, 1451.1, 1534.4, 1733.4, 2857.4, 2925.2; HRMS (ESI-TOF) *m*/*z* calcd for C~18~H~14~NO~3~ \[M + H\]^+^: 292.0974, found 292.0971.

### Ethyl Pyreno\[4,5-*d*\]oxazole-10-carboxylate (**4c**) {#sec4.2.3}

The compound was prepared following **GP-I** employing pyrene-4,5-dione (1.0 mmol, 232 mg) and ethyl glycinate (1.1 mmol, 112 mg). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a reddish orange solid (268 mg, 0.85 mmol, 85% yield). mp 146--148 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 11.54 (t, *J* = 7.2 Hz, 3H), 4.63 (q, *J*~1~ = 12 Hz, *J*~2~ = 7.2 Hz, 2H), 7.97--8.13 (m, 4H), 8.18 (d, *J* = 6.9 Hz, 2H), 8.53 (d, *J* = 7.5 Hz, 1H), 8.81 (d, *J* = 7.5 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 14.3, 63.1, 119.0, 119.5, 120.6, 123.5, 124.4, 124.7, 126.1, 126.4, 126.7, 126.8, 127.3, 128.2, 131.7, 131.8, 135.5, 147.1, 152.1, 156.3; FT-IR (KBr, cm^--1^): 668.9, 1215.8, 1732.5, 2927.6, 3019.7; HRMS (ESI-TOF) *m*/*z* calcd for C~20~H~14~NO~3~ \[M + H\]^+^: 316.0974, found 316.0977.

### 2-Propylphenanthro\[9,10-*d*\]oxazole (**4d**)^[@ref92]−[@ref94]^ {#sec4.2.4}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and butyl amine (1.1 mmol, 0.11 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (235 mg, 0.90 mmol, 90% yield). ^1^H NMR (300 MHz, CDCl~3~): δ 1.02 (t, *J* = 6.9 Hz, 3H), 1.86--1.99 (m, 2H), 2.97 (t, *J* = 7.5 Hz, 2H), 7.50--7.64 (m, 4H) 8.08--8.11 (m, 1H), 8.42 (d, *J* = 7.8 Hz, 1H), 8.58 (q, *J*~1~ = 4.5 Hz, *J*~2~ = 7.8 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 13.9, 21.0, 30.8, 120.6, 121.1, 122.7, 123.4, 123.7, 128.8, 126.06, 126.13, 127.1, 127.3, 128.7, 128.9, 134.2, 144.7, 166.1.

### 2-Nonylphenanthro\[9,10-*d*\]oxazole (**4e**) {#sec4.2.5}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and decyl amine (1.1 mmol, 0.22 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a brown solid (297 mg, 0.86 mmol, 86% yield). mp 52--54 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 0.84--0.89 (m, 3H), 1.34--1.47 (m, 12H), 1.88--1.96 (m, 2H), 3.02 (t, *J* = 7.2 Hz, 2H), 7.53--7.70 (m, 4H), 7.13 (d, *J* = 7.8 Hz, 1H), 8.48 (d. *J* = 7.8 Hz, 1H), 8.58--8.61 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 14.0, 22.6, 27.3, 28.8, 29.2, 29.3, 31.8, 120.4, 120.9, 122.5, 123.2, 123.5, 125.6, 125.8, 126.0, 127.0, 127.1, 128.5, 128.7, 134.1, 144.5, 166.0; FT-IR (KBr, cm^--1^): 754.9, 1215.6, 1346.8, 1560.2, 1579.6, 2855.1, 2927.0; HRMS (ESI-TOF) *m*/*z* calcd for C~24~H~28~NO \[M + H\]^+^: 346.2171, found 346.2166.

### 2-Benzylphenanthro\[9,10-*d*\]oxazole (**4f**) {#sec4.2.6}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and phenethylamine (1.1 mmol, 0.14 mL). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a yellow solid (238 mg, 0.77 mmol, 77% yield). mp 98--100 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 4.41 (s, 2H), 7.25--7.35 (m, 3H), 7.43 (d, *J* = 7.2 Hz, 2H), 7.61--7.71 (m, 4H), 8.14--8.17 (m, 1H), 8.49 (d, *J* = 7.8 Hz, 1H), 8.66--8.70 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 35.2, 120.6, 120.9, 122.6, 123.3, 123.5, 125.8, 126.0, 126.1, 127.1, 127.2, 128.6, 128.7, 128.8, 134.2, 135.3, 145.1, 163.7; FT-IR (KBr, cm^--1^): 711.3, 760.3, 1111.9, 1235.1, 1450.9, 1480.0, 1556.4, 2859.3, 2925.9; HRMS (ESI-TOF) *m*/*z* calcd for C~22~H~16~NO \[M + H\]^+^: 310.1232, found 310.1236.

### 2-(Phenanthro\[9,10-*d*\]oxazol-2-yl)ethanol (**4g**) {#sec4.2.7}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and ethanolamine (1.1 mmol, 0.07 mL). Purification by column chromatography (20% EtOAc-pet ether) afforded the title compound as a yellow solid (204 mg, 0.82 mmol, 82% yield). mp 174--176 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 4.99 (s, 2H), 6.14 (brs, 1H), 7.76--7.98 (m, 4H), 8.22--8.28 (m, 1H), 8.63 (d, 1H, *J* = 10.8 Hz), 9.25 (t, 2H, *J* = 9 Hz); ^13^C{^1^H} NMR (75 MHz, DMSO-*d*~6~): δ 56.1, 119.8, 119.9, 121.6, 123.6, 123.8, 125.0, 126.0, 126.4, 127.4, 127.5, 127.8, 128.1, 133.0, 143.7, 164.5; FT-IR (KBr, cm^--1^): 669.1, 756.6, 1215.9, 1408.8, 1456.3, 1634.2, 1727.9, 2927.1, 3019.8; HRMS (ESI-TOF) *m*/*z* calcd for C~16~H~12~NO~2~ \[M + H\]^+^: 250.0868, found 250.0871.

### 4-(Phenanthro\[9,10-*d*\]oxazol-2-yl-methyl)phenol (**4h**) {#sec4.2.8}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and tyrosine (1.1 mmol, 200 mg). Purification by column chromatography (20% EtOAc-pet ether) afforded the title compound as a yellow solid (195 mg, 0.60 mmol, 60% yield). mp 200--202 °C; ^1^H NMR (300 MHz, DMSO-*d*~6~): δ 4.29 (s, 2H), 6.72 (d, *J* = 8.4 Hz, 2H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.60--7.75 (m, 4H), 8.03--8.06 (m, 1H), 8.28--8.31 (m, 1H), 8.79 (t, *J* = 6.6 Hz, 2H), 9.37 (s, 1H); ^13^C{^1^H} NMR (75 MHz, DMSO-*d*~6~): δ 33.0, 115.0, 119.7, 119.8, 121.7, 123.5, 123.7, 124.9, 125.1, 125.8, 126.1, 127.2, 127.3, 127.7, 127.8, 129.5, 133.2, 143.6, 156.0, 164.4; FT-IR (KBr, cm^--1^): 723.7, 756.2, 809.8, 1256.7, 1450.9, 1518.7, 1594.6, 2924.0, 3399.9; HRMS (ESI-TOF) *m*/*z* calcd for C~22~H~16~NO~2~ \[M + H\]^+^: 326.1181, found 326.1178.

### 2-Methylphenanthro\[9,10-*d*\]oxazole (**4i**)^[@ref92]−[@ref94]^ {#sec4.2.9}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and alanine (1.1 mmol, 98 mg). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a light green solid (198 mg, 0.85 mmol, 85% yield). mp 128--130 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 2.72 (s, 3H), 7.48--7.68 (m, 4H), 8.07--8.09 (m, 1H), 8.41 (d, *J* = 7.8 Hz, 1H), 8.60 (d, *J* = 7.5 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 14.5, 120.4, 120.9, 122.4, 123.2, 123.5, 125.7, 125.85, 125.92, 127.0, 127.2, 128.5, 128.7, 134.2, 144.7, 162.3; FT-IR (KBr, cm^--1^): 723.1, 753.9, 1032.8, 1231.8, 1451.8, 1587.7, 1737.7, 2853.7, 2924.4.

### 2-Isopropylphenanthro\[9,10-*d*\]oxazole (**4j**) {#sec4.2.10}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and valine (1.1 mmol, 129 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (232 mg, 0.89 mmol, 89% yield). mp 76--78 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 0.74 (s, *J* = 6.9 Hz, 6H), 2.54--2.63 (m, 1H), 6.73--6.89 (m, 4H), 7.36 (d, *J* = 7.5 Hz, 1H), 7.70 (d, *J* = 7.8 Hz, 1H), 7.80--7.83 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 20.7, 29.1, 120.5, 121.0, 122.6, 123.3, 123.5, 125.7, 125.9, 126.1, 127.0, 127.2, 128.5, 128.7, 134.0, 144.4; FT-IR (KBr, cm^--1^): 722.7, 730.7, 755.7, 1033.7, 1078.8, 1350.7, 1450.3, 1558.0, 1578.4, 2928.9, 2962.1; HRMS (ESI-TOF) *m*/*z* calcd for C~18~H~16~NO \[M + H\]^+^: 262.1232, found 262.1229.

### 10-Isopropylpyreno\[4,5-*d*\]oxazole (**4k**) {#sec4.2.11}

The compound was prepared following **GP-I** employing pyrene-4,5-dione (1.0 mmol, 232 mg) and valine (1.1 mmol, 129 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (256 mg, 0.90 mmol, 90% yield). mp 96--98 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.61 (d, *J* = 6.9 Hz, 6H), 3.43--3.52 (m, 1H), 7.95--8.13 (m, 6H), 8.38 (d, *J* = 7.5 Hz, 1H); 8.72 (d, *J* = 7.8 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 20.8, 29.3, 117.4, 120.0, 120.3, 122.9, 124.8, 125.2, 126.0, 126.3, 127.3, 128.0, 131.7, 131.8, 145.2, 170.4; FT-IR (KBr, cm^--1^): 716.1, 826.2, 1178.6, 1303.8, 1564.2, 1603.8, 1726.9, 2925.6, 2969.4; HRMS (ESI-TOF) *m*/*z* calcd For C~21~H~16~NO \[M + H\]^+^: 286.1232, found 286.1227.

### 2-Isobutylphenanthro\[9,10-*d*\]oxazole (**4l**) {#sec4.2.12}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and leucine (1.1 mmol, 144 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a light brown solid (253 mg, 0.92 mmol, 92% yield). mp 68--70 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.03 (d, *J* = 6.6 Hz, 6H), 2.29--2.38 (m, 1H), 2.90 (d, *J* = 7.2 Hz, 2H), 7.54--7.67 (m, 4H), 8.13--8.16 (m, 1H), 8.46 (d, *J* = 7.8 Hz, 1H), 8.60--8.65 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 22.5, 27.9, 37.8, 120.6, 121.1, 122.7, 123.4, 123.6, 125.8, 126.05, 126.14, 127.1, 127.3, 128.6, 128.9, 134.3, 144.7, 165.5; FT-IR (KBr, cm^--1^): 724.3, 751.8, 1051.7, 1323.7, 1450.5, 1556.5, 1578.9, 2870.9, 2926.6, 2959.9; HRMS (ESI-TOF) *m*/*z* calcd for C~19~H~18~NO \[M + H\]^+^: 276.1388, found 276.1393.

### (*R*)-2-*sec*-Butylphenanthro\[9,10-*d*\]oxazole (**4m**) {#sec4.2.13}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and isoleucine (1.1 mmol, 144 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as yellow oil (250 mg, 0.91 mmol, 91% yield). \[*α*\]~D~^20^: +1.46° (*c* 2.667, CHCl~3~); ^1^H NMR (300 MHz, CDCl~3~): δ 0.95 (t, *J* = 7.5 Hz, 3H), 1.47 (d, *J* = 6.9 Hz, 3H), 1.74--1.83(m, 1H), 1.94--2.10 (m, 1H), 3.13--3.20 (m, 1H), 7.56--7.67 (m, 4H), 8.16--8.19 (m, 1H), 8.45--8.48 (m, 1H), 8.64--8.69 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 11.8, 18.3, 28.4, 36.1, 120.6, 121.1, 122.7, 123.3, 123.6, 125.7, 125.9, 126.2, 126.5, 127.0, 127.2, 128.5, 128.8, 134.1, 144.5, 169.4; FT-IR (KBr, cm^--1^): 724.1, 754.9, 1053.2, 1324.3, 1452.1, 1521.4, 1578.5, 1618.7, 2932.3, 2967.9; HRMS (ESI-TOF) *m*/*z* calcd for C~19~H~18~NO \[M + H\]^+^: 276.1388, found 276.1383.

### 2-(2-(Methylthio)ethyl)phenanthro\[9,10-*d*\]oxazole (**4n**) {#sec4.2.14}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and methionine (1.1 mmol, 164 mg). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a deep yellow solid (270 mg, 0.92 mmol, 92% yield). mp 82--84 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 2.17 (s, 3H), 3.07 (t, *J* = 7.5 Hz, 2H), 3.33 (s, *J* = 7.5 Hz, 2H), 7.57--7.69 (m, 4H), 8.11 (d, *J* = 7.5 Hz, 1H), 8.44 (d, *J* = 7.8 Hz, 1H), 8.60 (t, *J* = 4.1 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 15.6, 29.3, 31.3, 120.6, 120.9, 122.6, 123.4, 123.6, 125.9, 126.0, 126.2, 127.2, 127.3, 128.7, 128.9, 134.2, 144.8, 163.9; FT-IR (KBr, cm^--1^): 726.6, 763.0, 1054.3, 1321.7, 1432.1, 1558.7, 1576.7, 2853.3, 2922.5; HRMS (ESI-TOF) *m*/*z* calcd for C~18~H~16~NOS \[M + H\]^+^: 294.0953, found 294.0957.

### 1-(Phenanthro\[9,10-*d*\]oxazol-2-yl)ethanol (**4o**) {#sec4.2.15}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and threonine (1.1 mmol, 131 mg). Purification by column chromatography (10% EtOAc-pet ether) afforded the title compound as a yellow solid (218 mg, 0.83 mmol, 83% yield). mp 178--180 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.61 (dd, *J*~1~ = 1.8 Hz, *J*~2~ = 1.8 Hz, 3H), 5.04--5.10 (m, 1H), 6.00 (brs, 1H), 7.66--7.78 (m, 4H), 8.19 (d, *J* = 7.5 Hz, 1H), 8.36 (d, *J* = 7.8 Hz, 1H), 8.89 (t, *J* = 8.1 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 21.0, 62.1, 119.8, 121.6, 123.6, 123.8, 125.0, 125.8, 126.3, 127.3, 127.4, 127.8, 128.0, 132.8, 143.4, 167.1; FT-IR (KBr, cm^--1^): 715.8, 1245.9, 1426.8, 1501.3, 1654.2, 1729.5, 2928.7, 3087.5, 3325.6; HRMS (ESI-TOF) *m*/*z* calcd for C~17~H~14~NO~2~ \[M + H\]^+^: 264.1025, found 264.1030.

### Phenanthro\[9,10-*d*\]oxazole (**4p**)^[@ref92]−[@ref94]^ {#sec4.2.16}

The compound was prepared following **GP-I** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and glycine (1.1 mmol, 83 mg). Purification by column chromatography (1% EtOAc-pet ether) afforded the title compound as a yellow solid (193 mg, 0.88 mmol, 88% yield). ^1^H NMR (300 MHz, CDCl~3~): δ 7.59--7.70 (m, 4H), 8.12--8.18 (m, 2H), 8.47 (d, *J* = 7.5 Hz, 1H), 8.59 (d, *J* = 6.3 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 120.85, 120.93, 122.7, 123.4, 123.6, 126.0, 126.2, 127.2, 128.9, 129.4, 133.4, 144.5, 151.2.

### 5,10-Dibromo-2-methylphenanthro\[9,10-*d*\]oxazole (**4r**) {#sec4.2.17}

The compound was prepared following **GP-I** employing 1,6-dibromo-9,10-phenanthrenequinone (1.0 mmol, 366 mg) and alanine (1.1 mmol, 98 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a light yellow solid (320 mg, 0.82 mmol, 82% yield). mp 150--152 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 2.62 (s, 3H), 6.89 (d, 1H, *J* = 2.4 Hz), 6.95--6.98 (m, 1H), 7.17--7.28 (m, 1H), 7.27 (d, 1H, *J* = 8.7 Hz), 7.46--7.53 (m, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 15.1, 119.8, 119.9, 121.4, 121.8, 122.8, 128.9, 130.8, 131.4, 131.8, 135.0, 136.5, 137.6, 139.6, 140.2, 141.1, 164.0; FT-IR (KBr, cm^--1^): 744.7, 756.8, 1046.7, 1228.8, 1399.8, 1601.7, 1775.6, 2826.8, 2970.5; HRMS (ESI-TOF) *m*/*z* calcd for C~16~H~10~Br~2~NO \[M + H\]^+^: 389.9129, found 389.9133 (one of the major peaks).

### 5,10-Dibromo-2-isopropylphenanthro\[9,10-*d*\]oxazole (**4s**) {#sec4.2.18}

The compound was prepared following **GP-I** employing 1,6-dibromo-9,10-phenanthrenequinone (1.0 mmol, 366 mg) and valine (1.1 mmol, 129 mg). Purification by column chromatography (1% EtOAc-pet ether) afforded the title compound as a light yellow solid (335 mg, 0.80 mmol, 80% yield). mp 118--120 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.25 (d, *J* = 6 Hz, 6H), 2.85--2.94 (m, 1H), 6.98--7.04 (m, 1H), 7.07--7.11 (m, 1H), 7.32--7.41 (m, 1H), 7.53--7.66 (m, 3H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 21.1, 30.2, 119.1, 119.8, 120.6, 122.3, 123.0, 125.5, 128.5, 130.3, 133.7, 138.7, 140.1, 140.6; FT-IR (KBr, cm^--1^): 701.7, 748.7, 801.7, 1051.7, 1101.9, 1299.7, 1508.7, 1602.0, 1659.4, 2889.7, 2971.2; HRMS (ESI-TOF) *m*/*z* calcd for C~18~H~14~Br~2~NO \[M + H\]^+^: 417.9442, found 417.9437 (one of the major peaks).

General Procedure for the Synthesis of Oxazines **6a-i** (**GP-II**) {#sec4.3}
--------------------------------------------------------------------

To a mixture of phenanthrenequinone (**1**, 1.0 mmol) and α-substituted amine (**5a-e**)/amino acid ester (**5f, g**, 1.1 mmol, 1.1 equiv.) in dioxane (2 mL), I~2~ (20 mol %, 50 mg) was added, and the solution was refluxed under air to complete the reaction, which was monitored by TLC. Dioxane was removed from the reaction mixture, and the residue was purified by silica gel column chromatography using a suitable eluent to afford the desired product.

### 3-Phenyl-2*H*-Phenanthro\[9,10-*b*\]\[1,4\]oxazine (**6a**) {#sec4.3.1}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and α-methylbenzylamine (1.1 mmol, 0.14 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (247 mg, 0.80 mmol, 80% yield). mp 136--138 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 5.22 (s, 2H), 7.49--7.68 (m, 7H), 8.10 (t, *J* = 3.6 Hz, 2H), 8.25--8.28 (m, 1H), 8.61 (t, *J* = 9.3 Hz, 2H), 8.74 (d, *J* = 8.1 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 62.8, 122.5, 122.7, 122.77, 122.82, 124.7, 124.8, 125.1, 126.7, 126.8, 127.0, 127.1, 127.2, 128.8, 130.2, 130.7, 130.9, 135.8, 139.0, 154.7; FT-IR (KBr, cm^--1^): 722.6, 752.0, 1127.5, 1324.6, 1449.1, 2853.6, 2924.5; HRMS (ESI-TOF) *m*/*z* calcd for C~22~H~16~NO \[M + H\]^+^: 310.1232, found 310.1237.

### 11-Phenyl-10*H*-pyreno\[4,5-*b*\]\[1,4\]oxazine (**6b**) {#sec4.3.2}

The compound was prepared following **GP-II** employing pyrene-4,5-dione (1.0 mmol, 232 mg) and α-methylbenzylamine (1.1 mmol, 0.14 mL). Purification by column chromatography (20% DCM-pet ether) afforded the title compound as a yellow solid (246 mg, 0.74 mmol, 74% yield). mp 146--148 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 5.26 (s, 2H), 7.457.49 (m, 3H), 7.90--8.11 (m, 8H), 8.43 (d, *J* = 7.8 Hz, 1H), 8.90 (dd, *J*~1~ = 1.5 Hz, *J*~2~ = 6 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 62.8, 119.8, 120.0, 121.5, 123.8, 124.3, 125.3, 125.6, 126.0, 126.3, 126.7, 127.7, 128.7, 129.2, 130.9, 131.0, 135.7, 140.0, 155.0; FT-IR (KBr, cm^--1^): 717.3, 825.1, 1051.7, 1384.6, 1455.5, 1567.5, 1646.3, 2857.4, 2932.2; HRMS (ESI-TOF) *m*/*z* calcd for C~24~H~16~NO \[M + H\]^+^: 334.1232, found 334.1227.

### 3-(Naphthalen-2-yl)-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine (**6c**) {#sec4.3.3}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and 1-(naphthalen-2-yl)-ethylamine (1.1 mmol, 0.13 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow crystalline solid (291 mg, 0.81 mmol, 81% yield). mp 104--106 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 5.13 (s, 2H), 7.19--7.74 (m, 8H), 7.80--7.99 (m, 3H), 8.28--8.34 (m, 1H), 8.58--8.78 (m, 3H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 65.6, 122.4, 122.67, 122.74, 122.9, 124.2, 124.6, 125.0, 125.2, 125.3, 125.9, 126.3, 126.6, 126.8, 127.0, 127.2, 127.3, 128.3, 128.6, 130.1, 130.7, 133.0, 134.1, 134.5, 139.0, 157.1; FT-IR (KBr, cm^--1^): 718.6, 749.3, 756.5, 1026.2, 1235.2, 1508.1, 1674.4, 2852.0, 2923.0; HRMS (ESI-TOF) *m*/*z* calcd for C~26~H~18~NO \[M + H\]^+^: 360.1388, found 360.1393.

### 3-*p*-Tolyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine (**6d**) {#sec4.3.4}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and 1-(4-methylphenyl)-ethylamine (1.1 mmol, 0.16 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (242 mg, 0.75 mmol, 75% yield). mp 118--120 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 2.41 (s, 3H), 5.19 (s, 2H), 7.30 (d, *J* = 8.4 Hz, 2H), 7.54--7.68 (m, 4H), 7.99 (d, *J* = 8.1 Hz, 2H), 8.24--8.27 (m, 1H), 8.58--8.64 (m, 2H), 8.73--8.76 (m, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 21.5, 62.6, 122.3, 122.5, 122.6, 124.6, 124.7, 124.9, 126.5, 126.6, 127.0, 129.4, 130.1, 130.4, 133.0, 138.8, 141.3, 154.7; FT-IR (KBr, cm^--1^): 721.9, 755.9, 1032.4, 1126.2, 1179.5, 1384.2, 1494.5, 1608.1, 2853.1, 2923.9; HRMS (ESI-TOF) *m*/*z* calcd for C~23~H~18~NO \[M + H\]^+^: 324.1388, found 324.1386.

### 2-Methyl-3-phenyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine (**6e**) {#sec4.3.5}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and α-ethylbenzylamine (1.1 mmol, 0.16 mL). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a yellow solid (258 mg, 0.80 mmol, 80% yield). mp 172--174 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.43 (d, *J* = 6.6 Hz, 3H), 5.80 (q, *J* = 6.9 Hz, 1H), 7.42--7.72 (m, 7H), 8.12--8.15 (m, 2H), 8.30--8.33 (m, 1H), 8.60--8.66 (m, 2H), 8.82 (dd, *J*~1~ = 0.6 Hz, *J*~2~ = 9 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 16.1, 67.6, 122.4, 122.5, 122.7, 123.4, 124.9, 125.5, 126.6, 126.7, 126.8, 127.0, 127.9, 128.4, 128.7, 130.0, 130.7, 132.8, 135.4, 136.3, 157.8; FT-IR (KBr, cm^--1^): 682.5, 760.5, 1057.9, 1427.8, 1564.1, 2853.9, 2925.5; HRMS (ESI-TOF) *m*/*z* calcd for C~23~H~18~NO \[M + H\]^+^: 324.1388, found 324.1383.

### 3-Cyclohexyl-4*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine (**6f**) {#sec4.3.6}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and 1-cyclohexylethylamine (1.1 mmol, 0.16 mL). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a pale yellow low melting solid (215 mg, 0.68 mmol, 68% yield). ^1^H NMR (300 MHz, CDCl~3~): δ 1.51--1.63 (m, 4H), 1.73--1.77 (m, 2H), 1.84--1.88 (m, 2H), 2.13--2.23 (m, 2H), 2.84--2.92 (m, 1H),6.81 (s, 1H), 7.52--7.64 (m, 5H), 8.05--8.08 (m, 1H), 8.26--8.28 (m, 1H), 8.66 (d, *J* = 8.1 Hz, 2H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 26.0, 29.7, 31.7, 37.8, 99.6, 120.3, 121.1, 122.6, 123.4, 123.6, 123.9, 124.8. 125.2, 126.75, 126.83, 127.6, 128.0, 128.4, 147.8, 163.1; FT-IR (KBr, cm^--1^): 754.3, 1215.7, 1450.9, 1632.5, 1728.5, 2854.6, 2927.0, 3019.2; HRMS (ESI-TOF) *m*/*z* calcd for C~22~H~22~NO \[M + H\]^+^: 316.1701, found 316.1697.

### Ethyl 2-Phenyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine-3-carboxylate (**6g**)^[@ref95]^ {#sec4.3.7}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and phenylalanine ethyl ester (1.1 mmol, 193 mg). Purification by column chromatography (8% EtOAc-pet ether) afforded the title compound as a yellow solid (271 mg, 0.71 mmol, 71% yield). ^1^H NMR (300 MHz, CDCl~3~): δ 1.41 (*t*, *J* = 7.2 Hz, 3H), 4.41--4.46 (m, 2H), 6.60 (s, 1H), 7.17--7.22 (m, 3H), 7.33--7.37 (m, 2H), 7.54--7.68 (m, 4H), 8.32--8.35 (m, 1H), 8.54 (dd, *J*~1~ = 8.1 Hz, *J*~2~ = 15 Hz, 2H), 8.64 (dd, *J*~1~ = 1.2 Hz, *J*~2~ = 15 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 14.1, 29.6, 62.2, 122.3, 122.7, 122.8, 123.4, 123.5, 124.4, 125.4, 126.7, 126.9, 127.4, 128.5, 128.6, 129.0, 129.5, 132.1, 135.6, 139.5, 147.4, 163.3.

### Ethyl 2-Phenyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine-3-carboxylate (**6h**) {#sec4.3.8}

The compound was prepared following **GP-II** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and tyrosine ethyl ester (1.1 mmol, 209 mg). Purification by column chromatography (15% EtOAc-pet ether) afforded the title compound as a deep yellow solid (322 mg, 0.81 mmol, 81% yield). mp 192--194 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.39 (t, *J* = 7.2 Hz, 3H), 4.40 (q, *J* = 6.9 Hz, 2H), 6.49 (s, 1H), 6.60 (d, *J* = 8.7 Hz, 2H), 7.20 (d, *J* = 10.5 Hz, 2H), 7.51--7.66 (m, 5H), 8.28 (d, *J* = 7.8 Hz, 1H), 8.46--8.57 (m, 2H), 8.65 (d, *J* = 8.1 Hz, 1H); ^13^C{^1^H} NMR (75 MHz, DMSO-*d*~6~): δ 13.5, 61.2, 70.8, 115.1, 121.5, 122.2, 122.47, 122.54, 122.8, 123.5, 124.7, 125.2, 125.8, 126.9, 127.3, 128.2, 128.3, 128.5, 130.8, 138.2, 148.1, 158.0, 161.9; FT-IR (KBr, cm^--1^): 724.4, 755.0, 1170.0, 1229.5, 1514.2, 1613.1, 1715.7, 2853.4, 2924.7, 3370.8; HRMS (ESI-TOF) *m*/*z* calcd For C~25~H~20~NO~4~ \[M + H\]^+^: 398.1392, found 398.1388.

### 4,5-Dibromo-11-phenyl-10*H*-pyreno\[4,5-*b*\]\[1,4\]oxazine (**6i**) {#sec4.3.9}

The compound was prepared following **GP-II** employing 4,5-dibromopyrene-4,5-dione (1.0 mmol, 390 mg) and α-methylbenzylamine (1.1 mmol, 0.14 mL). Purification by column chromatography (15% DCM-pet ether) afforded the title compound as a bright yellow solid (344 mg, 0.70 mmol, 70% yield). mp 156--158 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 4.93 (s, 2H), 7.64--7.68 (m, 3H), 8.10--8.30 (m, 8H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 60.7, 118.8, 119.0, 120.5, 122.8, 123.3, 124.3, 124.6, 124.7, 125.3, 125.7, 126.7, 127.7, 128.2, 129.9, 130.0, 135.1, 139.1, 155.0; FT-IR (KBr, cm^--1^): 720.2, 900.1, 1021.5, 1121.5, 1314.9, 1422.7, 1601.7, 1678.6, 2823.2, 2954.7; HRMS (ESI-TOF) *m*/*z* calcd for C~24~H~14~Br~2~NO \[M + H\]^+^: 489.9442, found 489.9447 (one of the major peaks).

General Procedure for the Synthesis of Oxazine-2-ones **8a**--**c** (**GP-III**) {#sec4.4}
--------------------------------------------------------------------------------

To a mixture of phenanthrenequinone (**1**, 1.0 mmol) and amino acid ester (**5i**--**k**, 1.1 mmol, 1.1 equiv.) in dioxane (2 mL), I~2~ (20 mol %, 50 mg) was added, and the solution was refluxed under air to complete the reaction, which was monitored by TLC. Dioxane was removed from the reaction mixture, and the residue was purified by silica gel column chromatography using a suitable eluent to afford the desired product.

### Ethyl 2-Phenyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazine-3-carboxylate (**8a**) {#sec4.4.1}

The compound was prepared following **GP-III** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and alanine ethyl ester (1.1 mmol, 117 mg). Purification by column chromatography (8% EtOAc-pet ether) afforded the title compound as a yellow solid (201 mg, 0.77 mmol, 77% yield). mp 198--200 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 2.66 (s, 3H), 7.63--7.75 (m, 4H), 8.42 (d, *J* = 8.1 Hz, 1H), 8.56--8.62 (m, 2H), 8.77--8.79 (m, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 21.3, 122.4, 122.5, 122.7, 123.4, 126.9, 127.4, 127.7, 128.0, 128.3, 129.0, 130.8, 131.3, 141.1, 153.6; FT-IR (KBr, cm^--1^): 723.7, 763.3, 1086.3, 1396.5, 1731.5, 1741.8, 2853.0, 2923.3. HRMS (ESI-TOF) *m*/*z* calcd For C~17~H~12~NO~2~ \[M + H\]^+^: 262.0868, found 262.0864.

### 3-Isopropyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazin-2-one (**8b**) {#sec4.4.2}

The compound was prepared following **GP-III** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and valine ethyl ester (1.1 mmol, 145 mg). Purification by column chromatography (3% EtOAc-pet ether) afforded the title compound as a yellow solid (201 mg, 0.77 mmol, 77% yield). mp 148--150 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.40--1.43 (m, 6H), 3.48--3.56 (m, 1H), 7.61--7.70 (m, 4H), 8.39 (d, *J* = 7.8 Hz, 1H), 8.50--8.56 (m, 2H), 8.80 (d, *J* = 7.8 Hz, 1H). ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 20.0, 32.1, 122.4, 122.6, 122.7, 123.4, 123.5, 126.9, 127.4, 127.6, 128.0, 128.6, 128.9, 131.2, 153.0, 160.5; FT-IR (KBr, cm^--1^): 723.1, 751.1, 1036.3, 1451.7, 1623.9, 1731.3, 2853.6, 2925.8. HRMS (ESI-TOF) *m*/*z* calcd for C~19~H~16~NO~2~ \[M + H\]^+^: 290.1181, found 290.1176.

### 3-Isopropyl-2*H*-phenanthro\[9,10-*b*\]\[1,4\]oxazin-2-one (**8c**) {#sec4.4.3}

The compound was prepared following **GP-III** employing 9,10-phenanthrenequinone (1.0 mmol, 208 mg) and leucine ethyl ester (1.1 mmol, 159 mg). Purification by column chromatography (2% EtOAc-pet ether) afforded the title compound as a pale yellow solid (218 mg, 0.72 mmol, 72% yield). mp 106--108 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 1.01 (d, *J* = 6.6 Hz, 6H), 2.39--2.43 (m, 1H), 2.83 (d, *J* = 6.9 Hz, 2H), 7.54--7.66 (m, 4H), 8.25 (d, *J* = 7.8 Hz, 1H), 8.40--8.44 (m, 2H), 8.65--8.68 (m, 1H); ^13^C{^1^H} NMR (75 MHz, CDCl~3~): δ 22.6, 26.3, 42.5, 122.3, 122.4, 122.6, 123.2, 123.3, 126.8, 127.2, 127.5, 127.8, 128.3, 128.8, 131.0, 140.6, 153.4, 155.7. FT-IR (KBr, cm^--1^): 725.2, 764.7, 1193.4, 1293.8, 1397.2, 1451.1, 1495.8, 1554.6, 1734.2, 2870.4, 2926.6, 2955.6. HRMS (ESI-TOF) *m*/*z* calcd for C~20~H~18~NO~2~ \[M + H\]^+^: 304.1338, found 304.1333.
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